Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study

Rinaldo Pellicano, .

Palabras clave: Helicobacter pylori

Descargas

La descarga de datos todavía no está disponible.
  • Rinaldo Pellicano Unit of Gastroenterology, Molinette-SGAS Hospitals, Via Cavour 31, 10126 Turin, Turin 10123, Italy

Referencias

1. Roldán IJ, Castaño R, Navas MC. Mutaciones del gen ARN ribosómico 23S de Helicobacter pylori asociadas con resistencia a claritromicina en pacientes atendidos en una unidad de endoscopia de Medellín, Colombia. Biomédica. 2019;39(Supl.2):117-29.
2. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155:1372-82.
3. Argueta EA, Moss SF. Treatment of Helicobacter pylori. Curr Opin Gastroenterol. 2019;35:544-50.
4. O’Connor A, Liou JM, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2019. Helicobacter. 2019;24:e12640.
5. Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: Current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-15.
6. Fernández-Salazar L, Valle-Muñoz J. Treating Helicobacter pylori infection in the face of growing antibiotic resistance. Revista Española de Enfermedades Digestivas. 2019;111:653-4.
7. Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia. Biomédica. 2019:1;39:125-34.
8. Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;1.
9. Smith SM, O’Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35:6-13.
10. Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. Scand J Gastroenterol. 2018;53:661-4.
11. Seo JW, Park JY, Shin TS, Kim JG. The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body. BMC Gastroenterol. 2019;19:140.
12. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30.
13. Otero WA, Trespalacios AA, Otero L, Vallejo MT, Torres-Amaya M, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015;30:17-33.
14. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter. 2019;24:e12597.
15. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212-39.
16. Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, et al. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex. 2018;83:325-41.
17. Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475.
18. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018;16:992-1002.
19. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.
20. Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016;39:697-721.
21. Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018;64:310-21.
22. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-67.
23. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870-8.
24. Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41:768-75.
25. Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019;24:e12554.
Cómo citar
Pellicano, R. (2019). Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study. Biomédica, 39(4), 811-815. Recuperado a partir de https://revistabiomedica.org/index.php/biomedica/article/view/5310
Publicado
2019-12-01
Sección
Cartas al editor